Oramed Pharmaceuticals: Monday’s Top Stock

Even though the markets took a beating over the past week and biotech stocks experienced a broader industry sell-off, one stock in this space stood out as the clear winner on the market on Monday. Shares of Oramed Pharmaceuticals (NASDAQ: ORMP  ) were up more than 25% today, ahead of the company's report of phase 2 results for its oral insulin drug 0801 on Jan. 30. For diabetes-drug makers, oral insulin has long been a holy grail, and if these trial results are strong, the company will probably have no problem finding a partner, if not a buyer. In this video, Motley Fool health-care analyst David Williamson discusses why investors are jumping in today ahead of the news, and why this upcoming binary event could either be huge or devastating for the stock. He also tells investors in MannKind (NASDAQ: MNKD  ) why they may need to watch this event closely, and why success here for Oramed could give MannKind trouble down the road.

What's the best way to invest in biotech stocks?
The best way to play the biotech space is to find companies that shun the status quo and instead discover revolutionary, groundbreaking technologies. In The Motley Fool's brand-new free report "2 Game-Changing Biotechs Revolutionizing the Way We Treat Cancer," find out about a new technology that Big Pharma is endorsing through partnerships, and the two companies that are set to profit from this emerging drug class. Click here to get your copy today.

Read/Post Comments (2) | Recommend This Article (2)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On January 27, 2014, at 10:45 PM, theeseer wrote:

    ORMP is not a threat to MNKD's Afreeza for quite some time if at all. They have yet to begin FDA 3 and Afreeza is more than just an inhaler. Its patented insulin is "prandial" meaning it mimics the natural insulin faster and more like the human pancreas. The "dreamboat" less than palm size inhaler can be adapted to many other drug delivery systems.

    Afreeza is ready to go and anxiously awaited by those that were trial subjects and was almost approved before except for a request to test their newly introduced tiny inhaler which was done with FDA cooperation. Finally this market is huge and various combinations of treatments will be worked out between Doctor and patient. As with asthmatics many patients will no doubt become comfortable with the inhaler long before ORMP's drug hits the market and will stick with it's convenience and fast action.

  • Report this Comment On January 29, 2014, at 9:56 AM, theeseer wrote:

    Why Afreeza is needed now! ORMP will find its place later after FDA 3 etc.

    Artificial Pancreas (AP) & MannKind’s Afrezza Study Results Interview - Jan 24, 2014

    Search for "Maintaining Glucose Control at Mealtime" article just posted 4 days ago...

    DiabetesCare dot net interviews Dr. Howard Zisser - MD, director of research and technology at the Sansum Diabetes Research Institute, in collaboration with the University of California, Santa Barbara (UCSB) in collaboration with the University of California, Santa Barbara (UCSB) - about the ultra-rapid inhaled insulin in collaboration with a artificial pancreas in a clinical study, which was funded by JDRF.

    Below are the comments about the study's results:

    1) JDRF’s Aaron Kowalski, PhD, vice president of treatment therapies, stated, quote the early results of this exciting study are compelling. While more data are required, this protocol represents a potentially revolutionary way of combining the artificial pancreas with a simple-to-use inhaled insulin to significantly improve blood sugar levels. unquote.

    2) Dr. Zisser: quote The inhaled insulin gives us another arrow in our quiver—so to speak—to manage diabetes. I think it will be a great drug, especially for type 2 diabetes. Glucose monitoring has gotten much better and people can see how their decisions and activities affect their glucose in real time. Not only the value, but what direction it’s heading in, and with this learning, make better decisions in their care.

Add your comment.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2811900, ~/Articles/ArticleHandler.aspx, 9/2/2015 3:18:25 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

David Williamson

The Motley Fool's Healthcare Analyst, I specialize in Pharma, Biotech, and how the ACA (Obamacare) is changing the business of healthcare in America. Follow me on Twitter for breaking stock news, policy thoughts, and misc musings...

Today's Market

updated Moments ago Sponsored by:
DOW 16,275.58 217.23 1.35%
S&P 500 1,935.76 21.91 1.14%
NASD 4,712.48 76.37 1.65%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

9/2/2015 3:02 PM
MNKD $3.74 Up +0.03 +0.67%
MannKind Corp CAPS Rating: **
ORMP $5.79 Up +0.24 +4.32%
Oramed Pharmaceuti… CAPS Rating: **